Elevation Oncology Inc expected to post a loss of 22 cents a share - Earnings Preview

Elevation Oncology

28/02/2025 14:08

Elevation Oncology Inc ELEV.OQ ELEV.O is expected to show no change in quarterly revenue when it reports  results on March 4 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Elevation Oncology Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Elevation Oncology Inc is $6.50​, above​ its last closing price of $0.52. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.20
-0.20
-0.22
Missed
-10.6
Jun. 30 2024
-0.22
-0.22
-0.18
Beat
19.5
Mar. 31 2024
-0.20
-0.20
-0.23
Missed
-13.7​
Dec. 31 2023
-0.27
-0.24
-0.19
Beat
20
​​Sep. 30 2023
-0.31
-0.32
-0.25
Beat
21.9
Jun. 30 2023
-0.26
-0.32
-0.37
Missed
-15​
Mar. 31 2023
-0.62
-0.59
-0.72
Missed
-21.7
Dec. 31 2022
-0.92
-0.78
-0.82
Missed
-4.9

This summary was machine generated February 28 at 14:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)